Pemazyre (Pemigatinib).

Pemazyre is a kinase inhibitor used for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. 

Recommended Dosage: The recommended dosage is 13.5 mg orally once a day for 2 consecutive weeks followed by 1 week off therapy, in 3 week cycles. Continue treatment until the disease is progressive or unacceptable toxicity occurs. 

Take pemazyre tablets with or without food at around the same time every day. Swallow tablets completely. Do not chew, crush, split, or dissolve tablets. In case the patient misses any dose by 4 or more hours or in case vomiting occurs, dosing should be resumed with the upcoming scheduled dose.

• Tablets of pemazyre can cause RPED, which may cause signs/symptoms such as blurred vision, visual floaters, or photopsia. Comprehensive ophthalmological examination needs to be done including OCT before initiating pemazyre 9 mg / 4.5 mg / 13.5 mg tablet therapy and every 2 months for the initial 6 months and every 3 months thereafter while on treatment. 
• Monitor patients for hyperphosphatemia and start a low phosphate diet when the level of serum phosphate is > 5.5 mg/dL. For the serum phosphate levels > 7 mg/dL, start phosphate lowering therapy and withhold, reduce the dose, or permanently interrupt pemazyre tablet 4.5mg / 9mg / 13.5mg based on time-span and severity of hyperphosphatemia. 
• Findings in animal study and its mechanism of action suggest that pemazyre may cause fetal harm in cases administered to pregnant females. Advise females reproductive age to use effective contraception while on treatment with pemazyre tablet 13.5mg / 9mg / 4.5mg and for 1 week after the final dose. 

What documents are required to import PEMAZYRE to India?

PEMAZYRE (Pemigatinib) tablets can be imported by patients or government hospitals in the patients’ names. The following documentation is required to import the product:

• Valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s Identity Proof (issued by the government of India).

How does the order confirm?

The order will be confirmed only after the receipt of:

• Valid prescription from a doctor.
• Import permit if applicable.

Is PEMAZYRE available in India?

PEMAZYRE (pemigatinib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds is the facilitator providing input on:

• Availability in India (Delhi, Mumbai, Kolkata, Hyderabad, Ahmedabad, Chennai, Bangalore, and Pune, etc.)
• Medicine Price.
• Finding genuine and reliable sources from Canada, Europe, USA, and Australia.
• Ensuring 100% transparency.

PEMAZYRE can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

Urgent Meds can facilitate the supply of PEMAZYRE (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for Pemazyre price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is proficient in sourcing PEMAZYRE (Cancer Treatment Medicines) from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.

What is the Generic Name for the trade name drug Pemazyre®?

Pemigatinib is the Generic Name for the trade name drug Pemazyre®.

What is the Manufacturer Name of Pemazyre®?

Pemazyre® is manufactured by Incyte Corporation.

Is Pemazyre® approved by the FDA?

Yes, Pemazyre® is approved by the FDA. Date of approval: April 17, 2020.

What is Pemazyre®?

Pemazyre® is the first FDA-approved prescription agent aimed to treat adult patients with bile duct cancer (cholangiocarcinoma) that has spread or is difficult to be removed by surgery:

• who have already been treated with previous therapy, and
• whose tumor has a certain kind of abnormal “FGFR2” gene.

What is the dosage and form of Pemazyre® supplied?

Pemazyre® is supplied as Tablets: 4.5mg, 9mg & 13.5mg for oral administration.

What are the most common side effects due to Pemazyre®?

The most common side effects due to Pemazyre® include: nail toxicity, hyperphosphatemia, alopecia, diarrhea, fatigue, dysgeusia, constipation, nausea, stomatitis, dry eye, dry mouth, vomiting, arthralgia, decreased appetite, back pain, abdominal pain, hypophosphatemia, and dry skin.

How much does Pemigatinib cost in India?

The pemigatinib cost in India is less and reasonable. In order to procure this cholangiocarcinoma medication authentically, you can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Pemazyre®?

Store the tablets of Pemazyre at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).